Etsuro Hamaya

Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension

Akimitsu Miyauchi, Rajani Dinavahi, Daria B. Crittenden et al. · Archives of Osteoporosis · 2019 · 52 citations · Full text

Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial

Junichi Takada, Rajani Dinavahi, Akimitsu Miyauchi et al. · Journal of Bone and Mineral Metabolism · 2019 · 30 citations

Bone Health, Medicine, Osteoarthritis +8

Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosis

Toshitaka Nakamura, Jian Li Liu, Hirotoshi Morii et al. · Journal of Bone and Mineral Metabolism · 2006 · 27 citations

Bone Disease, Skeletal Trauma, Bone Health +7

Assessing the effect of baseline status of serum bone turnover markers and vitamin D levels on efficacy of teriparatide 20 μg/day administered subcutaneously in Japanese patients with osteoporosis

Takanori Yamamoto, Mika Tsujimoto, Etsuro Hamaya et al. · Journal of Bone and Mineral Metabolism · 2012 · 26 citations

Baseline Status, Bone Disease, Bone Health +8

Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk in Japan

Saeko Fujiwara, Etsuro Hamaya, Wakana Goto et al. · Bone · 2011 · 24 citations

Bone Disease, Skeletal Trauma, Bone Health +8